News

New combination therapy for ovarian cancer shows positive r...

New combination therapy for ovarian cancer shows positive results in Phase I clinical trials

January 7, 2014

A new combination therapy developed by researchers at the Roswell Park Cancer Institute has showed positive results in 60% of women with recurrent ovarian cancer. To develop the new therapy, researchers took advantage of the fact that ovarian cancer cells have abnormally high a marker called NY-ESO-1 on their surfaces. Researchers gave patients a drug … Continued

OCRF Research Finds New “Chemoimmunotherapy” Ma...

OCRF Research Finds New “Chemoimmunotherapy” May Be New Treatment Option

January 6, 2014

New research funded by OCRF shows that treatment with the drug decitabine, prior to administration of chemotherapy and a cancer vaccine, yielded clinical benefit for women with recurrent ovarian cancer. This suggests that this combinatorial “chemoimmunotherapy” may provide a new treatment option for patients with this disease. Results of this phase I clinical trial, which … Continued

New Guidelines on Risk, Genetic Counseling & Testing f...

New Guidelines on Risk, Genetic Counseling & Testing for BRCA-related Cancer

December 30, 2013

(December 30, 2013)   The U.S. Preventive Services Task Force (Task Force) has issued a final recommendation statement on Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-related Cancer in Women. This final recommendation statement applies to women who have no signs or symptoms of a BRCA-related cancer (cancer of the breast, ovary, fallopian tube, or … Continued

High Volume Hospitals and Providers Improve Survival

High Volume Hospitals and Providers Improve Survival

December 20, 2013

(December 20, 2013)  Researchers have found that for women with advanced-stage ovarian cancer, being treated at a high volume hospital with a high volume provider, leads to improved survival.  The research was published online today in Gynecologic Oncology. Among patients with advanced-stage ovarian cancer, the provider combination of high volume hospital/high volume provider is an … Continued

Treatment in New Study on Mice with Ovarian Cancer has Posi...

Treatment in New Study on Mice with Ovarian Cancer has Positive Results

December 17, 2013

A targeted drug delivery system developed at Rutgers University could possibly make ovarian cancer more treatable.  The study results published in Clinical Cancer Research also indicated the new system could increase survival rates in ovarian cancer.  Read the full article here.    

New OCRF Research on Ovarian Cancer Proliferation, Migratio...

New OCRF Research on Ovarian Cancer Proliferation, Migration, and Response to Therapy

December 11, 2013

Research funded by Ovarian Cancer Research Fund shows that adipose derived stromal cells derived from the human omentum can promote ovarian cancer proliferation, migration, chemoresistance and radiation resistance in-vitro. The research, funded in part through an OCRF grant to senior author Ann Klopp, MD, PhD was published online last week in PLoS One. The researchers hypothesized … Continued

OCRF Research Sheds Light on Ovarian Cancer Origins in BRCA...

OCRF Research Sheds Light on Ovarian Cancer Origins in BRCA Mutation Carriers

December 10, 2013

A team of current and former OCRF grantees at Brigham and Women’s Hospital, Harvard Medical School and Dana-Farber Cancer Institute has developed genetically engineered mouse models of high-grade serous ovarian cancer that shed light on the pathogenesis of ovarian cancer for BRCA1/2 mutation carriers.  These models, which target the cell of origin (fallopian tube secretory cells) and recreate key genetic … Continued

Scientists Ask: Does Ovarian Cancer Have a Smell?

Scientists Ask: Does Ovarian Cancer Have a Smell?

November 25, 2013

George Preti, who works at the Monell Chemical Senses Center as an organic chemist, and an interdisciplinary team that includes physicists and veterinarians at the University of Pennsylvania are using an electronic box to explore whether cancer has a smell.  In diseases that affect our metabolism, we secrete smells that can be indicative of what … Continued

OCRF Research Shows that Combining Targeted Agents is Effec...

OCRF Research Shows that Combining Targeted Agents is Effective Against Ovarian Cancer

November 18, 2013

New research funded in part by OCRF has shown that combining microRNA and siRNAs may be an effective new approach to developing better targeted therapies for ovarian cancer.  The research was reported in the November 2013 issue of Cancer Discovery, where the findings were also highlighted in an editorial commentary.  The research was funded in … Continued

Use of a Chemoresponse Assay Improves Clinical Outcomes

Use of a Chemoresponse Assay Improves Clinical Outcomes

November 7, 2013

Research published in the November 2013 issue of Gynecologic Oncology reports that the use of the chemoresponse assay ChemoFx can lead to improved clinical outcomes for women undergoing treatment for ovarian cancer. The goal of this clinical trial, which took nearly ten years to complete, was to determine the association of chemoresponse assay results with … Continued

Quality of life: Primary Debulking Surgery versus Neo-adjuv...

Quality of life: Primary Debulking Surgery versus Neo-adjuvant Chemotherapy

November 5, 2013

An international group of researchers examined quality of life factors for ovarian cancer patients enrolled in a large European clincial trial (EORTC 55971).  They compared the quality of life patients who had primary debulking surgery versus those who had neo-adjuvant chemotherapy, followed by surgery. The results, which are published in the journal Gynecologic Oncology, showed … Continued

New Study find Hot Ovarian Cancer Cells are Easier to Kill

New Study find Hot Ovarian Cancer Cells are Easier to Kill

October 23, 2013

Oregon State University researchers have found that using nanotechnology with heat and cytotoxic drugs can kill up to 95% of ovarian cancer cells.  While there is still additional research that needs to be done, the results of the initial study are promising for the future of ovarian cancer treatments.  Read full article here.